CI / The Cigna Group - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

SUPPLEMENTAL INDENTURE NO. 8

Exhibit 4.1 Execution Version SUPPLEMENTAL INDENTURE NO. 8 THIS SUPPLEMENTAL INDENTURE NO. 8, dated as of September 4, 2025 (this “Supplemental Indenture”), between THE CIGNA GROUP, a corporation duly organized and existing under the laws of the State of Delaware (the “Company”), and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, a national banking association duly organized and existing under the

UNITED STATES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 4, 2025 The Cigna Group (Exact name of registrant as specified in its charter) Delaware 001-38769 82-4991898 (State or other jurisdiction of incorporation) (Commission File N

CALCULATION OF FILING FEES TABLE (Form Type) The Cigna Group (Exact Name of Registrant as Specified in its Charter)

Exhibit 107 CALCULATION OF FILING FEES TABLE 424(b)(5) (Form Type) The Cigna Group (Exact Name of Registrant as Specified in its Charter) The prospectus supplement to which this Exhibit is attached is a final prospectus for the related offerings.

$1,000,000,000 4.500% Senior Notes due 2030 $1,250,000,000 4.875% Senior Notes due 2032 $1,500,000,000 5.250% Senior Notes due 2036 $750,000,000 6.000% Senior Notes due 2056 Underwriting Agreement

Exhibit 1.1 $1,000,000,000 4.500% Senior Notes due 2030 $1,250,000,000 4.875% Senior Notes due 2032 $1,500,000,000 5.250% Senior Notes due 2036 $750,000,000 6.000% Senior Notes due 2056 Underwriting Agreement September 2, 2025 BofA Securities, Inc. One Bryant Park New York, New York 10036 Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 HSBC Securities (USA) Inc. 66 Huds

The Cigna Group $1,000,000,000 4.500% Senior Notes due 2030 $1,250,000,000 4.875% Senior Notes due 2032 $1,500,000,000 5.250% Senior Notes due 2036  $750,000,000 6.000% Senior Notes due 2056

TABLE OF CONTENTS Filed Pursuant to Rule 424(B)(5) Registration No. 333-289983 PROSPECTUS SUPPLEMENT (To Prospectus dated September 2, 2025) $4,500,000,000   The Cigna Group $1,000,000,000 4.500% Senior Notes due 2030 $1,250,000,000 4.875% Senior Notes due 2032 $1,500,000,000 5.250% Senior Notes due 2036  $750,000,000 6.000% Senior Notes due 2056 We are offering $1,000,000,000 of our 4.500% Senior

THE CIGNA GROUP Pricing Term Sheet September 2, 2025

Free Writing Prospectus (to the Preliminary Prospectus Supplement dated September 2, 2025) Filed Pursuant to Rule 433 Registration Statement No.

SUBJECT TO COMPLETION, DATED SEPTEMBER 2, 2025

TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed.

Calculation of Filing Fee Tables Form S-3 (Form Type) The Cigna Group (Exact Name of Registrant as Specified in its Charter)

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) The Cigna Group (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 2, 2025 The Cigna Group

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 2, 2025 The Cigna Group (Exact name of registrant as specified in its charter) Delaware 001-38769 82-4991898 (State or other jurisdiction of incorporation) (Commission File N

As filed with the Securities and Exchange Commission on September 2, 2025

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on September 2, 2025 Registration No.

SECURITIES AND EXCHANGE COMMISSION

Exhibit 25 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2)☐ U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION (Exact name of Trustee as specified in its charter) 91-1821036 I.R.S. Empl

Revolving Credit and Letter of Credit Agreement, dated as of April 24, 2025, with the banks named therein, JPMorgan Chase Bank, N.A., as administrative agent, and BofA Securities, Inc., Citibank, N.A., Morgan Stanley Senior Funding, Inc. and Wells Fargo Securities, LLC, as joint lead arrangers and joint bookrunners

exh102cigna-5xyearrevol Exhibit 10.2 ═══════════════════════════════════════ REVOLVING CREDIT AND LETTER OF CREDIT AGREEMENT Dated as of April 24, 2025 Among THE CIGNA GROUP, THE GUARANTORS FROM TIME TO TIME PARTY HERETO, THE BANKS FROM TIME TO TIME PARTY HERETO, and JPMORGAN CHASE BANK, N.A., as Administrative Agent ═══════════════════════════════════════ JPMORGAN CHASE BANK, N.A., BofA SECURITIE

Agreement and Release between The Cigna Group and Eric Palmer dated April 15, 2025

Exhibit 10.1 AGREEMENT AND RELEASE This Agreement and Release is dated March 10, 2025, and is between Eric Palmer (you), and the Company. You and the Company (defined below) intend to be legally bound by the Agreement and are entering into it in reliance on the promises made to each other in this Agreement. Under the Agreement, your employment will end, and you and the Company agree to settle all

The Cigna Group Reports Strong Second Quarter 2025 Results, Reaffirms 2025 Adjusted EPS Outlook

Exhibit 99.1 Press Release INVESTOR RELATIONS CONTACT: Ralph Giacobbe 860-787-7968 [email protected] MEDIA CONTACT: Justine Sessions 860-810-6523 [email protected] The Cigna Group Reports Strong Second Quarter 2025 Results, Reaffirms 2025 Adjusted EPS Outlook • Total revenues for the second quarter 2025 increased 11% to $67.2 billion • Shareholders’ net income for the s

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 31, 2025 The Cigna Group (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 31, 2025 The Cigna Group (Exact name of registrant as specified in its charter) Delaware 001-38769 82-4991898 (State or other jurisdiction of incorporation) (Commission File Numbe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38769 The Cigna Group (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 30, 2025 The

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 30, 2025 The Cigna Group (Exact name of registrant as specified in its charter) Delaware 001-38769 82-4991898 (State or other jurisdiction of incorporation) (Comm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K ☒ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 15(

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K ☒ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38769 A.Full title of the plan and the addre

The Cigna Group Announces Appointment of Michael J. Hennigan to Board of Directors

Exhibit 99.1 The Cigna Group Announces Appointment of Michael J. Hennigan to Board of Directors BLOOMFIELD, Conn., June 2, 2025 – Global health company The Cigna Group (NYSE:CI) announced today that Michael J. Hennigan has been appointed to the organization's Board of Directors. His appointment is effective June 2. Mr. Hennigan is the Executive Chairman of Marathon Petroleum Corporation (MPC), an

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 30, 2025 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-499189

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 20, 2025 The Cigna Group (Exact name of registrant as specified in its charter) Delaware 001-38769 82-4991898 (State or other jurisdiction of incorporation) (Commission File Number

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 2, 2025 The Cigna Group (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 2, 2025 The Cigna Group (Exact name of registrant as specified in its charter) Delaware 001-38769 82-4991898 (State or other jurisdiction of incorporation) (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38769 The Cigna Group (Exac

The Cigna Group Reports Strong First Quarter 2025 Results, Raises 2025 Outlook

Exhibit 99.1 INVESTOR RELATIONS CONTACT: Ralph Giacobbe 860-787-7968 [email protected] MEDIA CONTACT: Justine Sessions 860-810-6523 [email protected] The Cigna Group Reports Strong First Quarter 2025 Results, Raises 2025 Outlook • Total revenues for the first quarter 2025 increased 14% to $65.5 billion • Shareholders’ net income for the first quarter 2025 was $1.3 billi

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2025 The Cigna Group (Exact name of registrant as specified in its charter) Delaware 001-38769 82-4991898 (State or other jurisdiction of incorporation) (Commission File Num

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 15, 2025 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-4991

The Cigna Group Completes Sale of Medicare Businesses to HCSC

Exhibit 99.1 The Cigna Group Press Release The Cigna Group Completes Sale of Medicare Businesses to HCSC BLOOMFIELD, Conn., March 19, 2025 – Global health company The Cigna Group (NYSE: CI) today announced the successful completion of the sale of its Medicare Advantage, Cigna Supplemental Benefits, Medicare Part D, and CareAllies businesses to Health Care Service Corporation (HCSC). The divestment

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 19, 2025 The Cigna Group (Exact name of registrant as specified in its charter) Delaware 001-38769 82-4991898 (State or other jurisdiction of incorporation) (Commission File Numb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   ) Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   ) Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ De

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 10, 2025 The Cigna Group (Exact name of registrant as specified in its charter) Delaware 001-38769 82-4991898 (State or other jurisdiction of incorporation) (Commission File Numb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 3, 2025 The Cigna Group (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 3, 2025 The Cigna Group (Exact name of registrant as specified in its charter) Delaware 001-38769 82-4991898 (State or other jurisdiction of incorporation) (Commission File Numbe

Securities Transactions and Insider Trading Policy

Exhibit 19.1 I. General Description Title: Securities Transactions and Insider Trading Effective Date: October 18, 2022 Prepared By/ Last Revised By: Office of the Corporate Secretary Regulation: SEC Rule 10b-5 II. Purpose and Scope Purpose: It is The Cigna Group's policy to comply with securities laws prohibiting insider trading, to establish standards of conduct for employees and others who obta

Subsidiaries of the Registrant

Exhibit 21 Exhibit 21 – Subsidiaries of the Registrant Listed below are subsidiaries of The Cigna Group as of December 31, 2024 with their jurisdictions of organization.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38769 The Cigna Group

The Cigna Group Non-Employee Director Compensation Program, amended and restated effective July 24, 2024

Exhibit 10.14(c) The Cigna Group Non-Employee Director Compensation Program I. Board and Committee Retainers A. Annual Board Retainer. Each non-employee director of The Cigna Group (“Director”), with the exception of the Chair of the Board of Directors, receives $335,000 annually for Board membership (“Annual Board Retainer”). A portion ($120,000) of the Annual Board Retainer is paid in cash and t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 30, 2025 The Cigna Group (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 30, 2025 The Cigna Group (Exact name of registrant as specified in its charter) Delaware 001-38769 82-4991898 (State or other jurisdiction of incorporation) (Commission File Nu

The Cigna Group Reports Fourth Quarter and Full Year 2024 Results, Establishes 2025 Outlook and Increases Dividend

Exhibit 99.1 INVESTOR RELATIONS CONTACT: Ralph Giacobbe 860-787-7968 [email protected] MEDIA CONTACT: Justine Sessions 860-810-6523 [email protected] The Cigna Group Reports Fourth Quarter and Full Year 2024 Results, Establishes 2025 Outlook and Increases Dividend • Total revenues for 2024 increased 27% to $247.1 billion • Shareholders’ net income for 2024 was $3.4 bill

THE CIGNA GROUP 900 Cottage Grove Road Bloomfield, Connecticut 06002

THE CIGNA GROUP 900 Cottage Grove Road Bloomfield, Connecticut 06002 VIA EDGAR January 16, 2025 United States Securities and Exchange Commission Division of Corporation Finance Office of Finance 100 F Street, N.

THE CIGNA GROUP 900 Cottage Grove Road Bloomfield, Connecticut 06002

THE CIGNA GROUP 900 Cottage Grove Road Bloomfield, Connecticut 06002 VIA EDGAR November 21, 2024 United States Securities and Exchange Commission Division of Corporation Finance Office of Finance 100 F Street, N.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38769 The Cigna Group (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 31, 2024 The Cigna Group (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 31, 2024 The Cigna Group (Exact name of registrant as specified in its charter) Delaware 001-38769 82-4991898 (State or other jurisdiction of incorporation) (Commission File Nu

The Cigna Group Reports Strong Third Quarter 2024 Results, Reaffirms 2024 Adjusted EPS Outlook

Exhibit 99.1 Press Release INVESTOR RELATIONS CONTACT: Ralph Giacobbe 860-787-7968 [email protected] MEDIA CONTACT: Justine Sessions 860-810-6523 [email protected] The Cigna Group Reports Strong Third Quarter 2024 Results, Reaffirms 2024 Adjusted EPS Outlook • Total revenues for the third quarter 2024 increased 30% to $63.7 billion • Shareholders’ net income for the thi

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 3, 2024 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38769 The Cigna Group (Exact

The Cigna Group Reports Strong Second Quarter 2024 Results

Exhibit 99.1 Press Release INVESTOR RELATIONS CONTACT: Ralph Giacobbe 860-787-7968 [email protected] MEDIA CONTACT: Justine Sessions 860-810-6523 [email protected] The Cigna Group Reports Strong Second Quarter 2024 Results • Total revenues for the second quarter 2024 increased 25% to $60.5 billion • Shareholders’ net income for the second quarter 2024 was $1.5 billion,

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 1, 2024 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-4991

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K ☒ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 15(

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K ☒ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38769 A.Full title of the plan and the addre

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 14, 2024 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-49918

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 6, 2024 The Cigna Group (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 6, 2024 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-499189

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38769 The Cigna Group (Exac

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 2, 2024 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-4991898

The Cigna Group Reports Strong First Quarter 2024 Results, Raises 2024 Outlook

Exhibit 99.1 Press Release INVESTOR RELATIONS CONTACT: Ralph Giacobbe 860-787-7968 [email protected] MEDIA CONTACT: Justine Sessions 860-810-6523 [email protected] The Cigna Group Reports Strong First Quarter 2024 Results, Raises 2024 Outlook • Total revenues for the first quarter 2024 were $57.3 billion • Shareholders’ net loss for the first quarter 2024 was $0.3 billi

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 25, 2024 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-4991

Revolving Credit and Letter of Credit Agreement, dated as of April 25, 2024, with the banks named therein, JPMorgan Chase Bank, N.A., as administrative agent, BofA Securities, Inc., Citibank, N.A., Morgan Stanley Senior Funding, Inc. and Wells Fargo Securities, LLC, as joint lead arrangers and joint bookrunners.

Exhibit 10.1 ═══════════════════════════════════════ REVOLVING CREDIT AND LETTER OF CREDIT AGREEMENT Dated as of April 25, 2024 Among THE CIGNA GROUP, THE GUARANTORS FROM TIME TO TIME PARTY HERETO, THE BANKS FROM TIME TO TIME PARTY HERETO, and JPMORGAN CHASE BANK, N.A., as Administrative Agent ═══════════════════════════════════════ JPMORGAN CHASE BANK, N.A., BofA SECURITIES, INC., CITIBANK, N.A.,

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 24, 2024 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-4991

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   ) Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ De

United States Securities and Exchange Commission Washington, D.C. 20549 NOTICE OF EXEMPT SOLICITATION Pursuant to Rule 14a-103

United States Securities and Exchange Commission Washington, D.C. 20549 NOTICE OF EXEMPT SOLICITATION Pursuant to Rule 14a-103 Name of the Registrant: The Cigna Group Name of persons relying on exemption: National Center for Public Policy Research Address of persons relying on exemption: 2005 Massachusetts Ave. N.W., Washington, D.C 20036 Written materials are submitted pursuant to Rule 14a-6(g) (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   ) Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ De

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   ) Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ De

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   ) Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒

The Cigna Group Raises Long-Term Growth Target, and Launches New Innovative Solutions at 2024 Investor Day

Exhibit 99.1 PRESS RELEASE The Cigna Group Raises Long-Term Growth Target, and Launches New Innovative Solutions at 2024 Investor Day Highlights: · Raises long-term average annual adjusted EPS1 growth target to 10%-14% · Affirms 2024 adjusted EPS1 guidance of at least $28.25 · Announces solutions and innovations for some of the greatest health care challenges: GLP-1 spend, mental health care acces

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 7, 2024 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-49918

Incentive Compensation Clawback Policy

Exhibit 97.1 The Cigna Group Incentive Compensation Clawback Policy (As Adopted on October 25, 2023 Pursuant to NYSE Rule 303A.14) 1.Overview. The Board of Directors (the “Board”) of The Cigna Group (the “Company”) has adopted this Incentive Compensation Clawback Policy (the “Policy”) which requires the recoupment of certain incentive-based compensation in accordance with the terms herein and is i

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38769 The Cigna Group

Description of Securities

Exhibit 4.7 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a summary of the material terms of the Common Stock, par value $0.01 per share of The Cigna Group (“Cigna” or the “Company”). This summary is not complete and is qualified by Cigna’s restated certificate of incorporation, which we refer to as the certific

Subsidiaries of the Registrant

Exhibit 21 Exhibit 21 – Subsidiaries of the Registrant Listed below are subsidiaries of The Cigna Group as of December 31, 2023 with their jurisdictions of organization.

Offer letter for Brian Evanko dated January 16, 2024

Exhibit 10.26 David M. Cordani Chairman and CEO January 16, 2024 Brian Evanko Dear Brian: I am pleased to confirm that the People Resources Committee (PRC) has approved the following changes to your compensation package effective February 5, 2024 in connection with the assumption of your expanded role as EVP, CFO and President & CEO Cigna Healthcare: Base Salary – Your base salary will increase to

Offer Letter for Eric P. Palmer dated January 16, 2024

Exhibit 10.23 David M. Cordani Chairman and CEO January 16, 2024 Eric Palmer Dear Eric: I am pleased to confirm that the People Resources Committee (PRC) has approved the following changes to your compensation package effective February 5, 2024 in connection with the assumption of your expanded role as EVP, Enterprise Strategy and President & CEO Evernorth: Base Salary – Your base salary will rema

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 14, 2024 The Cigna Group

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 14, 2024 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-4

The Cigna Group Announces $3.2 Billion Accelerated Stock Repurchase

Exhibit 99.1 Press Release The Cigna Group Announces $3.2 Billion Accelerated Stock Repurchase Bloomfield, Conn. February 15, 2024 – Global health company The Cigna Group (NYSE: CI) will repurchase $3.2 billion of common stock through accelerated stock repurchase agreements (the “ASR Agreements”) with Deutsche Bank AG and Bank of America, N.A. (the “Counterparties”). The ASR Agreements are part of

CI / The Cigna Group / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv0605-cignagroupthe.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: Cigna Group/The Title of Class of Securities: Common Stock CUSIP Number: 125523100 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the r

between The Cigna Group and U.S. Bank Trust Company, National Association, as trustee

Exhibit 4.1 SUPPLEMENTAL INDENTURE NO. 7 THIS SUPPLEMENTAL INDENTURE NO. 7, dated as of February 13, 2024 (this “Supplemental Indenture”), between THE CIGNA GROUP, a corporation duly organized and existing under the laws of the State of Delaware (the “Company”), and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, a national banking association duly organized and existing under the laws of the Unite

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 13, 2024 The Cigna Group

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 13, 2024 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-4

CALCULATION OF FILING FEES TABLE

Exhibit 107 CALCULATION OF FILING FEES TABLE The prospectus supplement to which this Exhibit is attached is a final prospectus for the related offerings.

The Cigna Group $1,000,000,000 5.000% Senior Notes due 2029 $750,000,000 5.125% Senior Notes due 2031 $1,250,000,000 5.250% Senior Notes due 2034 $1,500,000,000 5.600% Senior Notes due 2054

TABLE OF CONTENTS Filed Pursuant to Rule 424(B)(5) Registration No. 333-268633 Prospectus Supplement (To Prospectus dated December 1, 2022) $4,500,000,000   The Cigna Group $1,000,000,000 5.000% Senior Notes due 2029 $750,000,000 5.125% Senior Notes due 2031 $1,250,000,000 5.250% Senior Notes due 2034 $1,500,000,000 5.600% Senior Notes due 2054 We are offering $1,000,000,000 of our 5.000% Senior N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 5, 2024 The Cigna Group (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 5, 2024 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-49

$1,000,000,000 5.000% Senior Notes due 2029 $750,000,000 5.125% Senior Notes due 2031 $1,250,000,000 5.250% Senior Notes due 2034 $1,500,000,000 5.600% Senior Notes due 2054 Underwriting Agreement

Exhibit 1.1 Execution Version $1,000,000,000 5.000% Senior Notes due 2029 $750,000,000 5.125% Senior Notes due 2031 $1,250,000,000 5.250% Senior Notes due 2034 $1,500,000,000 5.600% Senior Notes due 2054 Underwriting Agreement February 5, 2024 Deutsche Bank Securities Inc. 1 Columbus Circle New York, New York 10019 Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 J.P. Morgan Securi

THE CIGNA GROUP Pricing Term Sheet February 5, 2024

Free Writing Prospectus (to the Preliminary Prospectus Supplement dated February 5, 2024) Filed Pursuant to Rule 433 Registration Statement No.

The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and we are not soliciting an offer to buy t

TABLE OF CONTENTS Filed Pursuant to Rule 424(B)(3) Registration No. 333-268633 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and we are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not perm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 2, 2024 The Cigna Group (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 2, 2024 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-49

The Cigna Group Reports Strong Fourth Quarter and Full Year 2023 Results, Raises 2024 Adjusted EPS Outlook, and Increases Dividend

Exhibit 99.1 Press Release INVESTOR RELATIONS CONTACT: Ralph Giacobbe 860-787-7968 [email protected] MEDIA CONTACT: Justine Sessions 860-810-6523 [email protected] The Cigna Group Reports Strong Fourth Quarter and Full Year 2023 Results, Raises 2024 Adjusted EPS Outlook, and Increases Dividend • Total revenues for 2023 were $195.3 billion • Shareholders’ net income for

The Cigna Group to Sell Medicare Businesses and CareAllies to Health Care Service Corporation (HCSC) Transaction Expected to be Accretive to Adjusted EPS1 in 2025 The Cigna Group Reaffirms 2024 Outlook and Long-Term Adjusted EPS1 Growth Target of 10-

Exhibit 99.1 PRESS RELEASE The Cigna Group to Sell Medicare Businesses and CareAllies to Health Care Service Corporation (HCSC) Transaction Expected to be Accretive to Adjusted EPS1 in 2025 The Cigna Group Reaffirms 2024 Outlook and Long-Term Adjusted EPS1 Growth Target of 10-13% Bloomfield, Conn., Jan. 31, 2024 – Global health company The Cigna Group (NYSE: CI) today announced that it has entered

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 31, 2024 The Cigna Group (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 31, 2024 The Cigna Group (Exact name of registrant as specified in its charter) Delaware 001-38769 82-4991898 (State or other jurisdiction of incorporation) (Commission File Nu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 16, 2024 The Cigna Group (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 16, 2024 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-49

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 16, 2024 The Cigna Group (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 16, 2024 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-49

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 29, 2023 The Cigna Group

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 29, 2023 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-4

Intends to Repurchase at Least $5 Billion of Common Stock by End of First Half of 2024, with Portion Executed Via ASR in First Quarter 2024 Reaffirms Previously Provided Outlook for Full-Year 2023

Exhibit 99.1 The Cigna Group Announces Significant Increase to Share Repurchase Program of $10 Billion Intends to Repurchase at Least $5 Billion of Common Stock by End of First Half of 2024, with Portion Executed Via ASR in First Quarter 2024 Reaffirms Previously Provided Outlook for Full-Year 2023 BLOOMFIELD, Conn., Dec. 10, 2023 /PRNewswire/ - Global health company The Cigna Group (NYSE: CI) tod

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 10, 2023 The Cigna Group

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 10, 2023 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-4

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 4, 2023 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-49

Raises 2023 Adjusted EPS, Revenue, and Cash Flow Outlook

Exhibit 99.1 Press Release INVESTOR RELATIONS CONTACT: Ralph Giacobbe 860-787-7968 [email protected] MEDIA CONTACT: Justine Sessions 860-810-6523 [email protected] The Cigna Group Reports Strong Third Quarter 2023 Results, Raises 2023 Adjusted EPS, Revenue, and Cash Flow Outlook • Total revenues in the third quarter were $49.0 billion • Shareholders’ net income for the thir

Offer Letter for Nicole S. Jones dated September 14, 2023

exh102xnjonesxofferxlet David M. Cordani Chairman and CEO September 14, 2023 Nicole Jones Dear Nicole: I am pleased to confirm that the People Resources Committee (PRC) has approved the following changes to your compensation package effective September 14, 2023 in connection with the assumption of your expanded role as EVP, Chief Administrative Officer & General Counsel:  Base Salary – will incre

Offer Letter for Noelle K. Eder dated September 14, 2023

exh101xnederxofferxlett David M. Cordani Chairman and CEO September 14, 2023 Noelle Eder Dear Noelle: I am pleased to confirm that the People Resources Committee (PRC) has approved the following changes to your compensation package effective September 14, 2023 in connection with the assumption of your expanded role as EVP Technology & Operations:  Base Salary – will increase to a pre-tax annualiz

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38769 The Cigna Group (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 2, 2023 The Cigna Group (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 2, 2023 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-49

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 14, 2023 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 11, 2023 The Cigna Group

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 11, 2023 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-

Restated Certificate of Incorporation of The Cigna Group

Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF THE CIGNA GROUP The undersigned hereby certifies on behalf of The Cigna Group as follows: 1. The present name of the corporation is The Cigna Group. The corporation was incorporated under the name "Halfmoon Parent, Inc." by the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware on March 6, 20

The Cigna Group Reports Strong Second Quarter 2023 Results

Exhibit 99.1 Press Release INVESTOR RELATIONS CONTACT: Ralph Giacobbe 860-787-7968 [email protected] MEDIA CONTACT: Justine Sessions 860-810-6523 [email protected] The Cigna Group Reports Strong Second Quarter 2023 Results • Total revenues in the second quarter were $48.6 billion • Shareholders’ net income for the second quarter was $1.5 billion, or $4.92 per share • Adjust

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 3, 2023 The Cigna Group (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 3, 2023 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-4991

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38769 The Cigna Group (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38769 A. Full title of the plan a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 5, 2023 The Cigna Group (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 5, 2023 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-499189

Offer letter for Noelle Eder dated July 22, 202

ederofferletter

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 5, 2023 The Cigna Group (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 5, 2023 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-4991898

The Cigna Group Reports Strong First Quarter 2023 Results, Raises 2023 Outlook

Exhibit 99.1 Press Release INVESTOR RELATIONS CONTACT: Ralph Giacobbe 860-787-7968 [email protected] MEDIA CONTACT: Justine Sessions 860-810-6523 [email protected] The Cigna Group Reports Strong First Quarter 2023 Results, Raises 2023 Outlook • Total revenues in the first quarter were $46.5 billion • Shareholders’ net income for the first quarter was $1.3 billion, or $4.24

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38769 The Cigna Group (Exac

Restated Certificate of Incorporation of the registrant effective as of April 26, 2023

Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF THE CIGNA GROUP The undersigned hereby certifies on behalf of The Cigna Group as follows: 1. The present name of the corporation is The Cigna Group. The corporation was incorporated under the name "Halfmoon Parent, Inc." by the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware on March 6, 20

Supplemental Pharmacy Benefit Management Model Disclosure

Exhibit 20.1 Supplemental Pharmacy Benefit Management Model Disclosure On each of April 13 and 20, 2023, Express Scripts, Inc. (“Express Scripts”) issued a press release announcing several actions to further evolve its pharmacy benefit management (“PBM”) model. The purpose of this disclosure is to provide additional information regarding Express Scripts’ business model that is described in the 202

The Cigna Group Announces Appointment of Dr. Philip Ozuah to Board of Directors

Exhibit 99.1 Press Release The Cigna Group Announces Appointment of Dr. Philip Ozuah to Board of Directors BLOOMFIELD, Conn., May 1, 2023 – Global health company The Cigna Group (NYSE:CI) today announced that Dr. Philip Ozuah has been appointed to the organization’s Board of Directors. His appointment is effective June 1, 2023. Since 2019, Dr. Philip Ozuah has served as the President and CEO of Mo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 26, 2023 The Cigna Group (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 26, 2023 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-4991

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 27, 2023 The Cigna Group (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 27, 2023 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-4991

Revolving Credit and Letter of Credit Agreement, dated as of April 27, 2023, with the banks named therein, JPMorgan Chase Bank, N.A., as administrative agent, BofA Securities, Inc., Citibank, N.A., Morgan Stanley Senior Funding, Inc. and Wells Fargo Securities, LLC, as joint lead arrangers and joint bookrunners.

Exhibit 10.1 EXECUTION VERSION ═══════════════════════════════════════ REVOLVING CREDIT AND LETTER OF CREDIT AGREEMENT Dated as of April 27, 2023 Among THE CIGNA GROUP, THE GUARANTORS FROM TIME TO TIME PARTY HERETO, THE BANKS FROM TIME TO TIME PARTY HERETO, and JPMORGAN CHASE BANK, N.A., as Administrative Agent ═══════════════════════════════════════ JPMORGAN CHASE BANK, N.A., BofA SECURITIES, INC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 26, 2023 The Cigna Group (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 26, 2023 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-4991

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   )

DEFA14A 1 ny20008678x2defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Onl

United States Securities and Exchange Commission Washington, D.C. 20549 NOTICE OF EXEMPT SOLICITATION Pursuant to Rule 14a-103 Name of the Registrant: Cigna Corporation Name of persons relying on exemption: Clean Yield Asset Management Address of per

United States Securities and Exchange Commission Washington, D.C. 20549 NOTICE OF EXEMPT SOLICITATION Pursuant to Rule 14a-103 Name of the Registrant: Cigna Corporation Name of persons relying on exemption: Clean Yield Asset Management Address of persons relying on exemption: 16 Beaver Meadow Rd, Norwich, VT 05055 Written materials are submitted pursuant to Rule 14a-6(g) (1) promulgated under the

REMEMBER: You can vote your shares online or by telephone. Please use the control number found on the enclosed proxy card and visit www.proxyvote.com to submit your instructions online, or if you received this letter by email, you may simply click th

April 10, 2023 Dear Shareholder: We have previously sent to you proxy materials for The Cigna Group Annual Meeting of Shareholders to be held on April 26, 2023.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   ) Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by Ru

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   ) Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐

Sixth Supplemental Indenture, dated as of March 7, 2023, between Cigna Corporation and U.S. Bank National Association, as trustee

Exhibit 4.1 SUPPLEMENTAL INDENTURE NO. 6 THIS SUPPLEMENTAL INDENTURE NO. 6, dated as of March 7, 2023 (this “Supplemental Indenture”), between THE CIGNA GROUP, a corporation duly organized and existing under the laws of the State of Delaware (the “Company”), and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, a national banking association duly organized and existing under the laws of the United St

$700,000,000 5.685% Senior Notes due 2026 $800,000,000 5.400% Senior Notes due 2033 Underwriting Agreement

Exhibit 1.1 $700,000,000 5.685% Senior Notes due 2026 $800,000,000 5.400% Senior Notes due 2033 Underwriting Agreement February 28, 2023 BofA Securities, Inc. One Bryant Park New York, New York 10036 Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 U.S. Bancorp Investments, Inc. 214 N. Tryon St., 26th Floor Charlotte, North Carolina 28202 as the Representatives of the several Underw

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 7, 2023 The Cigna Group (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 7, 2023 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-49918

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   ) Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box: ☒ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by Rul

The Cigna Group $700,000,000 5.685% Senior Notes due 2026 $800,000,000 5.400% Senior Notes due 2033

TABLE OF CONTENTS Filed Pursuant to Rule 424(B)(5) Registration No. 333-268633 Prospectus Supplement (To Prospectus dated December 1, 2022) $1,500,000,000   The Cigna Group $700,000,000 5.685% Senior Notes due 2026 $800,000,000 5.400% Senior Notes due 2033 We are offering $700,000,000 of our 5.685% Senior Notes due 2026 (the “3-Year Notes”) and $800,000,000 of our 5.400% Senior Notes due 2033 (the

CALCULATION OF FILING FEES TABLE

EX-FILING FEES 2 ny20007738x3ex107.htm FILING FEES TABLE Exhibit 107 CALCULATION OF FILING FEES TABLE The prospectus supplement to which this Exhibit is attached is a final prospectus for the related offerings. The maximum aggregate amount of those offerings is $1,499,234,000. Security Type Security Class Title Fee Calculation of Carry Forward Rule Amount Registered Proposed Maximum Offering Price

THE CIGNA GROUP Pricing Term Sheet February 28, 2023

Free Writing Prospectus (to the Preliminary Prospectus Supplement dated February 28, 2023) Filed Pursuant to Rule 433 Registration Statement No.

The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and we are not soliciting an offer to buy t

TABLE OF CONTENTS Filed Pursuant to Rule 424(B)(3) Registration No. 333-268633 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and we are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not perm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 27, 2023 The Cigna Group

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 27, 2023 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-4

Subsidiaries of the Registrant

Exhibit 21 – Subsidiaries of the Registrant Listed below are subsidiaries of The Cigna Group as of December 31, 2022 with their jurisdictions of organization.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38769 The Cigna Group

Amendment No.1 to the Cigna Long-Term Incentive Plan effective December 1, 2022

Exhibit 10.1(b) AMENDMENT NO. 1 TO THE CIGNA LONG-TERM INCENTIVE PLAN (Amended and Restated Effective as of April 28, 2021) WHEREAS, Cigna Corporation (“Cigna”), maintains the Cigna Long-Term Incentive Plan (Amended and Restated Effective as of April 28, 2021) (the “Plan”); and WHEREAS, under Section 16.1 of the Plan, the Board of Directors of Cigna (the “Board”) (or an authorized committee of the

CI / Cigna Corp / DODGE & COX - SC 13G/A Passive Investment

SC 13G/A 1 d390295dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1)* Cigna Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 125523100 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat

Amended and Restated By-laws of The Cigna Group

Exhibit 3.3 AMENDED AND RESTATED BY-LAWS OF THE CIGNA GROUP (A Delaware Corporation) Article I Offices Section 1. Registered Office. The registered office of The Cigna Group (hereinafter, the “Corporation”) within the State of Delaware shall be in the City of Wilmington, County of New Castle. Section 2. Other Offices. The Corporation may also have offices at such other places, both within and with

Restated Certificate of Incorporation of The Cigna Group

Exhibit 3.2 RESTATED CERTIFICATE OF INCORPORATION OF THE CIGNA GROUP The undersigned hereby certifies on behalf of The Cigna Group as follows: 1. The present name of the corporation is The Cigna Group. The corporation was incorporated under the name "Halfmoon Parent, Inc." by the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware on March 6, 20

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 13, 2023 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-4

Certificate of Amendment of Restated Certificate of Incorporation of Cigna Corporation

Exhibit 3.1 CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF CIGNA CORPORATION (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) Cigna Corporation, a corporation duly organized and existing under the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify that: 1. The Restated Certificate of Incorporation of the

CI / Cigna Corp / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Cigna Corp. Title of Class of Securities: Common Stock CUSIP Number: 125523100 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 3, 2023 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-

Cigna Reports Strong Fourth Quarter and Full Year 2022 Results, Establishes 2023 Guidance and Increases Dividend

Exhibit 99.1 Press Release INVESTOR RELATIONS CONTACT: Ralph Giacobbe 860-787-7968 [email protected] MEDIA CONTACT: Justine Sessions 860-810-6523 [email protected] Cigna Reports Strong Fourth Quarter and Full Year 2022 Results, Establishes 2023 Guidance and Increases Dividend • Total revenues for 2022 were $180.5 billion • Shareholders’ net income for 2022 was $6.7 billion, or $21.

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 30, 2022 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82

securities and exchange commission Washington, D.C. 20549 FORM T-1 Statement of Eligibility Under The Trust Indenture Act of 1939 of a Corporation Designated to Act as Trustee Check if an Application to Determine Eligibility of a Trustee Pursuant to

Exhibit 25 securities and exchange commission Washington, D.C. 20549 FORM T-1 Statement of Eligibility Under The Trust Indenture Act of 1939 of a Corporation Designated to Act as Trustee Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2) [] U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION (Exact name of Trustee as specified in its charter) 91-1821036 I.R.S. Em

As filed with the Securities and Exchange Commission on December 1, 2022

table of contents As filed with the Securities and Exchange Commission on December 1, 2022 Registration No.

Calculation of Filing Fee Tables Form S-3 (Form Type) Cigna Corporation. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities

EX-FILING FEES 5 ex107.htm EXHIBIT 107 Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Cigna Corporation. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 30, 2022 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 3, 2022 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38769 Cigna Corporation

Cigna Reports Strong Third Quarter 2022 Results, Raises 2022 Outlook

Exhibit 99.1 Press Release INVESTOR RELATIONS CONTACT: Ralph Giacobbe 860-787-7968 [email protected] MEDIA CONTACT: Justine Sessions 860-810-6523 [email protected] Cigna Reports Strong Third Quarter 2022 Results, Raises 2022 Outlook ? Total revenues in the third quarter were $45.3 billion ? Shareholders? net income for the third quarter was $2.8 billion, or $8.97 per share ? Adjust

Restated By-Laws of Cigna Corporation dated October 26, 2022

Exhibit 3.2 RESTATED BY-LAWS OF CIGNA CORPORATION (A Delaware Corporation) Article I Offices Section 1. Registered Office. The registered office of the Corporation within the State of Delaware shall be in the City of Wilmington, County of New Castle. Section 2. Other Offices. The Corporation may also have offices at such other places, both within and without the State of Delaware, as the Board of

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 26, 2022 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 13, 2022 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 8

Cigna Reports Strong Second Quarter 2022 Results, Raises 2022 Outlook

Exhibit 99.1 Press Release INVESTOR RELATIONS CONTACT: Ralph Giacobbe 860-787-7968 [email protected] MEDIA CONTACT: Justine Sessions 860-810-6523 [email protected] Cigna Reports Strong Second Quarter 2022 Results, Raises 2022 Outlook ? Total revenues in the second quarter were $45.5 billion ? Shareholders? net income for the second quarter was $1.6 billion, or $4.90 per share ? Adj

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38769 Cigna Corporation (Exa

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 4, 2022 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-49

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38769 A. Full title of the plan a

Cigna Announces $3.5 Billion Accelerated Stock Repurchase Agreements

Exhibit 99.1 Press Release Cigna Announces $3.5 Billion Accelerated Stock Repurchase Agreements Bloomfield, Conn. June 16, 2022 ? Global health services company Cigna Corporation (NYSE: CI) will repurchase $3.5 billion of common stock through accelerated stock repurchase agreements (the ?ASR Agreements?) with Mizuho Markets Americas LLC and Morgan Stanley & Co. LLC (the ?Counterparties?). The ASRs

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 15, 2022 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-499

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 3, 2022 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-4991

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 6, 2022 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission Fil

Cigna Reports Strong First Quarter 2022 Results, Raises 2022 Outlook

Exhibit 99.1 Press Release INVESTOR RELATIONS CONTACT: Ralph Giacobbe 860-787-7968 [email protected] MEDIA CONTACT: Justine Sessions 860-810-6523 [email protected] Cigna Reports Strong First Quarter 2022 Results, Raises 2022 Outlook ? Total revenues in the first quarter were $44.0 billion, and adjusted revenues1 were $44.1 billion ? Shareholders? net income for the first quarter wa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38769 Cigna Corporation (Ex

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 6, 2022 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-49918

Press release dated May 6, 2022.

Exhibit 99.1

Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 27, 2022 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-4991898 (IRS Emp

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 28, 2022 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-49

Revolving Credit and Letter of Credit Agreement, dated as of April 28, 2022, with the banks named therein, JPMorgan Chase Bank, N.A., as administrative agent, BofA Securities, Inc., Citibank, N.A., Morgan Stanley Senior Funding, Inc., MUFG Bank, LTD and Wells Fargo Securities, LLC, as joint lead arrangers and joint bookrunners

Exhibit 10.1 Execution Version ??????????????????????????????????????? REVOLVING CREDIT AND LETTER OF CREDIT AGREEMENT Dated as of April 28, 2022 Among CIGNA CORPORATION, THE GUARANTORS FROM TIME TO TIME PARTY HERETO, THE BANKS FROM TIME TO TIME PARTY HERETO, and JPMORGAN CHASE BANK, N.A., as Administrative Agent ??????????????????????????????????????? JPMORGAN CHASE BANK, N.A., BofA SECURITIES, I

SECURITIES & EXCHANGE COMMISSION WASHINGTON, D.C. 20549 NOTICE OF EXEMPT SOLICITATION

SECURITIES & EXCHANGE COMMISSION WASHINGTON, D.C. 20549 NOTICE OF EXEMPT SOLICITATION NAME OF REGISTRANT: Cigna Corporation NAME OF PERSONS RELYING ON EXEMPTION: Proxy Impact ADDRESSES OF PERSONS RELYING ON EXEMPTION: 5011 Esmond Ave., Richmond, CA 94805 Written materials are submitted pursuant to Rule 14a-6(g)(1) promulgated under the Securities Exchange Act of 1934. Submission is not required of

YOUR VOTE IS IMPORTANT: You can vote your shares online or by telephone. Please use the control number found on the enclosed proxy card and visit www.proxyvote.com to submit your instructions online; or if you received this letter by email, you may s

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ??? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Def

United States Securities and Exchange Commission Washington, D.C. 20549 NOTICE OF EXEMPT SOLICITATION Pursuant to Rule 14a-103 Name of the Registrant: Cigna Corporation Name of persons relying on exemption: Clean Yield Asset Management Address of per

United States Securities and Exchange Commission Washington, D.C. 20549 NOTICE OF EXEMPT SOLICITATION Pursuant to Rule 14a-103 Name of the Registrant: Cigna Corporation Name of persons relying on exemption: Clean Yield Asset Management Address of persons relying on exemption: 16 Beaver Meadow Rd, Norwich, VT 05055 Written materials are submitted pursuant to Rule 14a-6(g) (1) promulgated under the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ??) Filed by the Registrant ? Filed by a Party other than the Registrant ?? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? De

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ??) Filed by the Registrant ? Filed by a Party other than the Registrant ?? Check the appropriate box: ?? ? ? Preliminary Proxy Statement ?? ? ? Confidential, for Use of the Commission Only (as permitt

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ??? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Def

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38769 Cigna Corporati

Advisory Services Agreement by and between Cigna Corporation and Mr. Timothy Wentworth, dated as of November 3, 2021

Exhibit 10.30(c) ADVISORY SERVICES AGREEMENT This Advisory Services Agreement (?Agreement?) is made as of November 3, 2021 between Cigna Corporation (?Company?), and Timothy Wentworth (?Advisor?) (Company and Advisor together, the ?Parties?). WHEREAS, the Company has determined that it is in its best interests to have Advisor provide the Company with services as an Advisor during the Advisory Peri

Amended and Restated By-Laws of the registrant as last amended February 22, 2022

Exhibit 3.2 RESTATED BY-LAWS OF CIGNA CORPORATION (A Delaware Corporation) Article I Offices Section 1.Registered Office. The registered office of the Corporation within the State of Delaware shall be in the City of Wilmington, County of New Castle. Section 2.Other Offices. The Corporation may also have offices at such other places, both within and without the State of Delaware, as the Board of Di

Executive Retirement Agreement by and between Cigna Corporation and Matthew Manders, dated November 3, 2021

Exhibit 10.36(b) EXECUTIVE RETIREMENT AGREEMENT This Executive Retirement Agreement is dated as of November 3, 2021, and is between Matthew Manders (you), and the Company. You and the Company (defined below) intend to be legally bound by the Agreement, and are entering into it in reliance on the promises made to each other in this Agreement. Under the Agreement, your employment will end, and you a

Cigna Corporation Non-Employee Director Compensation Program, amended and restated effective January 1, 2022

Exhibit 10.17(a) Cigna Corporation Non-Employee Director Compensation Program I. Board and Committee Retainers A. Annual Board Retainer. Each non-employee director of Cigna Corporation (?Director?), with the exception of the Chair of the Board of Directors, receives $310,000 annually for Board membership (?Annual Board Retainer?). A portion ($120,000) of the Annual Board Retainer is paid in cash a

Executive Retirement Agreement by and between Cigna Corporation and Mr. Timothy Wentworth, dated as of November 3, 2021

Exhibit 10.30(b) EXECUTIVE RETIREMENT AGREEMENT This Executive Retirement Agreement is dated as of November 3, 2021, and is between Timothy Wentworth (you), and the Company. You and the Company (defined below) intend to be legally bound by the Agreement, and are entering into it in reliance on the promises made to each other in this Agreement. Under the Agreement, your employment will end, and you

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 24, 2022 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82

Advisory Services Agreement by and between Cigna Corporation and Matthew Manders, dated November 3, 2021

Exhibit 10.36(c) ADVISORY SERVICES AGREEMENT This Advisory Services Agreement (?Agreement?) is made as of November 3, 2021 between Cigna Corporation (?Company?), and Matthew Manders (?Advisor?) (Company and Advisor together, the ?Parties?). WHEREAS, the Company has determined that it is in its best interests to have Advisor provide the Company with services as an Advisor during the Advisory Period

Cigna Corporation Non-Employee Director Compensation Program, amended and restated effective April 1, 2022

Exhibit 10.17(b) Cigna Corporation Non-Employee Director Compensation Program I. Board and Committee Retainers A. Annual Board Retainer. Each non-employee director of Cigna Corporation (?Director?), with the exception of the Chair of the Board of Directors, receives $310,000 annually for Board membership (?Annual Board Retainer?). A portion ($120,000) of the Annual Board Retainer is paid in cash a

Subsidiaries of the Registrant

Exhibit 21 ? Subsidiaries of the Registrant Listed below are subsidiaries of Cigna Corporation as of December 31, 2021 with their jurisdictions of organization.

CI / Cigna Corp / DODGE & COX - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 0)* Cigna Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 125523100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sched

CI / Cigna Corp / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Cigna Corp. Title of Class of Securities: Common Stock CUSIP Number: 125523100 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13

Cigna Reports Fourth Quarter and Full Year 2021 Results, Expects Continued Revenue and Attractive Earnings Per Share Growth in 2022

Exhibit 99.1 Press Release INVESTOR RELATIONS CONTACT: Ralph Giacobbe 804-688-3400 [email protected] MEDIA CONTACT: Justine Sessions 860-810-6523 [email protected] Cigna Reports Fourth Quarter and Full Year 2021 Results, Expects Continued Revenue and Attractive Earnings Per Share Growth in 2022 ? Total revenues for 2021 were $174.1 billion, and adjusted revenues1 for 2021 were $174

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 3, 2022 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported) January 24, 2022 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware 001-38769 82-4991898 (State or other jurisdiction (Commission file number) (I.R.S

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 27, 2021 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82

Amended and Restated By-Laws of Cigna Corporation, dated as of December 2, 2021.

Exhibit 3.1 RESTATED BY-LAWS OF CIGNA CORPORATION (A Delaware Corporation) Article I Offices Section 1. Registered Office. The registered office of the Corporation within the State of Delaware shall be in the City of Wilmington, County of New Castle. Section 2. Other Offices. The Corporation may also have offices at such other places, both within and without the State of Delaware, as the Board of

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 2, 2021 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-4991898 (IRS E

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 29, 2021 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 4, 2021 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-

Amended and Restated By-Laws of Cigna Corporation as last amended

Exhibit 3.1 RESTATED BY-LAWS OF CIGNA CORPORATION (A Delaware Corporation) ARTICLE I Offices Section 1.Registered Office. The registered office of the Corporation within the State of Delaware shall be in the City of Wilmington, County of New Castle. Section 2.Other Offices. The Corporation may also have offices at such other places, both within and without the State of Delaware, as the Board of Di

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-38769 Cigna Corporation (

Cigna Reports Third Quarter 2021 Results, Raises 2021 Outlook

Exhibit 99.1 Press Release INVESTOR RELATIONS CONTACT: Alexis Jones 215-761-3637 [email protected] MEDIA CONTACT: Justine Sessions 860-810-6523 [email protected] Cigna Reports Third Quarter 2021 Results, Raises 2021 Outlook ? Total revenues in the third quarter were $44.3 billion, and adjusted revenues1 were $44.3 billion ? Shareholders? net income for the third quarter was $1.6 bill

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 20, 2021 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 8

Cigna Announces Leadership Changes to Continue Accelerating Business Growth

Exhibit 99.1 Press Release Cigna Announces Leadership Changes to Continue Accelerating Business Growth ? Eric Palmer promoted to president and chief executive officer, Evernorth ? Paul Sanford promoted to executive vice president, operations, Cigna Corporation ? Noelle Eder assumes leadership of global data, analytics, and automation as executive vice president and global chief information officer

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 2, 2021 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82

Cigna Reports Second Quarter 2021 Results

Exhibit 99.1 Press Release INVESTOR RELATIONS CONTACT: Alexis Jones 215-761-3637 [email protected] MEDIA CONTACT: Justine Sessions 860-810-6523 [email protected] Cigna Reports Second Quarter 2021 Results ? Total revenues in the second quarter were $43.1 billion, and adjusted revenues1 were $43.1 billion ? Shareholders? net income for the second quarter was $1.5 billion, or $4.25 per

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-38769 Cigna Corporation (Exact

As filed with the Securities and Exchange Commission on August 5, 2021

As filed with the Securities and Exchange Commission on August 5, 2021 Registration No.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 5, 2021 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-49

Amendment No. 2 to the Express Scripts, Inc. Executive Deferred Compensation Plan

Exhibit 10.3 AMENDMENT NO. 2 TO THE EXPRESS SCRIPTS, INC. EXECUTIVE DEFERRED COMPENSATION PLAN (As amended and restated effective December 20, 2018) WHEREAS, Cigna Corporation (the ?Company?) sponsors the Express Scripts Inc. Executive Deferred Compensation Plan (the ?Plan?) for the benefit of a select group of one or more management or highly compensated employees; and WHEREAS, the Company desire

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2021 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-49

Cigna Corporation Announces Updates to its Board of Directors

Exhibit 99.1 Press Release Cigna Corporation Announces Updates to its Board of Directors The Board of Directors: ? Honors the Retirement of Isaiah Harris, Jr., Chair of the Board of Directors ? Welcomes Neesha Hathi ? Elects David M. Cordani as Chair of the Board and Eric Wiseman as Lead Independent Director BLOOMFIELD, Conn. ? July 30, 2021 ? Global health service company Cigna Corporation (NYSE:

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 11-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 11-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38769 A.

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 28, 2021 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-4991

Form of Cigna Long-Term Incentive Plan: Restricted Stock Unit Grant Agreement

EX-10.4 5 exh104grantagreemntx21rsu.htm EX-10.4 Exhibit 10.4 Cigna Corporation Cigna Long-Term Incentive Plan: Restricted Stock Unit Grant Agreement Cigna Corporation (“Cigna”) has granted you the number of restricted stock units of Cigna set forth below in this Restricted Stock Unit Grant Agreement (“Restricted Stock Unit Grant” or “Grant”) under the Cigna Long-Term Incentive Plan (“Plan”). The d

Cigna Delivers Strong First Quarter 2021 Results, Raises 2021 Outlook

Exhibit 99.1 Press Release INVESTOR RELATIONS CONTACT: Alexis Jones 215-761-3637 [email protected] MEDIA CONTACT: Justine Sessions 860-810-6523 [email protected] Cigna Delivers Strong First Quarter 2021 Results, Raises 2021 Outlook ? Total revenues in the first quarter were $41.0 billion, and adjusted revenues1 were $41.0 billion ? Shareholders? net income for the first quarter was $

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to Commission file number 1-38769 Cigna Corporation (Exac

Form of Cigna Long-Term Incentive Plan: Restricted Stock Grant Agreement

Exhibit 10.3 Cigna Corporation Cigna Long-Term Incentive Plan: Restricted Stock Grant Agreement Cigna Corporation (?Cigna?) has granted you the number of shares of restricted stock of Cigna set forth below in this Restricted Stock Grant Agreement (?Restricted Stock Grant? or ?Grant?) under the Cigna Long-Term Incentive Plan (?Plan?). The date of your Restricted Stock Grant (?Grant Date?) and the d

Form of Cigna LTIP: Strategic Performance Share Grant Agreement

Exhibit 10.1 Cigna Corporation Cigna Long-Term Incentive Plan: Strategic Performance Share Grant Agreement Cigna Corporation (?Cigna?) has granted you the number of strategic performance shares set forth below in this Strategic Performance Share Grant Agreement (?Strategic Performance Share Grant? or ?Grant?) under the Cigna Long-Term Incentive Plan (?Plan?). The date of your Strategic Performance

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 7, 2021 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-49918

Form of Cigna Long-Term Incentive Plan: Nonqualified Stock Option Grant Agreement

Exhibit 10.2 Cigna Corporation Cigna Long-Term Incentive Plan: Nonqualified Stock Option Grant Agreement Cigna Corporation (?Cigna?) has granted you the option to purchase the number of shares of Cigna Common Stock set forth below in this Option Grant Agreement (?Option Grant?) under the Cigna Long-Term Incentive Plan (?Plan?). The date of your Option Grant (?Grant Date?), the dates on which your

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 6, 2021 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commissi

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 28, 2021 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-4991898 (IRS Emp

Cigna Long-Term Incentive Plan, amended and restated effective April 28, 2021

Exhibit 10.1 CIGNA LONG-TERM INCENTIVE PLAN (Amended and Restated Effective as of April 28, 2021) ARTICLE 1 Statement of Purpose The Cigna Long-Term Incentive Plan is intended to: (a) Reward the creation of long-term value for Cigna shareholders by providing key employees, non-employee directors, consultants, and other advisors of the Company with an opportunity to acquire an equity interest in Ci

REVOLVING CREDIT AND LETTER OF CREDIT AGREEMENT Dated as of April 29, 2021 CIGNA CORPORATION, THE GUARANTORS FROM TIME TO TIME PARTY HERETO, THE BANKS FROM TIME TO TIME PARTY HERETO, JPMORGAN CHASE BANK, N.A., as Administrative Agent JPMORGAN CHASE B

EXHIBIT 10.1 REVOLVING CREDIT AND LETTER OF CREDIT AGREEMENT Dated as of April 29, 2021 Among CIGNA CORPORATION, THE GUARANTORS FROM TIME TO TIME PARTY HERETO, THE BANKS FROM TIME TO TIME PARTY HERETO, and JPMORGAN CHASE BANK, N.A., as Administrative Agent JPMORGAN CHASE BANK, N.A., BofA SECURITIES, INC., CITIBANK, N.A., MORGAN STANLEY SENIOR FUNDING, INC. MUFG BANK, LTD., and WELLS FARGO SECURITI

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 29, 2021 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware 001-38769 82-4991898 (State or other jurisdiction of incorporation) (Commission File Nu

-

Notice of Exempt Solicitation NAME OF REGISTRANT: Cigna Corporation NAME OF PERSONS RELYING ON EXEMPTION: Proxy Impact ADDRESS OF PERSON RELYING ON EXEMPTION: 5011 Esmond Ave, Richmond CA.

- DEFA 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ?? Check the appropriate box: ?? Preliminary Proxy Statement ?? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ?? D

- DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ??? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Def

- DEF14A

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ??) Filed by the Registrant ? Filed by a Party other than the Registrant ?? Check the appropriate box: ?? ? ? Preliminary Proxy Statement ?? ? ? Confidential, for Use of the Commission Only (as permitt

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 8, 2021 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-499

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 1, 2021 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware 001-38769 82-4991898 (State or other jurisdiction of incorporation) (Commission File Num

$500,000,000 0.613% Senior Notes due 2024 $800,000,000 1.250% Senior Notes due 2026 $1,500,000,000 2.375% Senior Notes due 2031 $1,500,000,000 3.400% Senior Notes due 2051 Underwriting Agreement

Exhibit 1.1 EXECUTION VERSION $500,000,000 0.613% Senior Notes due 2024 $800,000,000 1.250% Senior Notes due 2026 $1,500,000,000 2.375% Senior Notes due 2031 $1,500,000,000 3.400% Senior Notes due 2051 Underwriting Agreement March 1, 2021 Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 Wells Fargo Se

SUPPLEMENTAL INDENTURE NO. 5

Exhibit 4.1 SUPPLEMENTAL INDENTURE NO. 5 THIS SUPPLEMENTAL INDENTURE NO. 5, dated as of March 3, 2021 (this ?Supplemental Indenture?), between CIGNA CORPORATION, a corporation duly organized and existing under the laws of the State of Delaware (the ?Company?), and U.S. BANK NATIONAL ASSOCIATION, a national banking association duly organized and existing under the laws of the United States of Ameri

CALCULATION OF REGISTRATION FEE

TABLE OF CONTENTS Filed pursuant to rule 424(b)(5) Registration No. 333-236877 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities ? ? Amount To Be Registered ? ? Aggregate Price Per Unit ? ? Aggregate Offering Price ? ? Amount of Registration Fee(1) 0.613% Senior Notes due 2024 ? ? $500,000,000 ? ? 100.000% ? ? $500,000,000 ? ? $54,550.00 1.250% Senior Notes due 2026 ? ? $800,000,00

CIGNA CORPORATION Pricing Term Sheet March 1, 2021

Free Writing Prospectus (to the Preliminary Prospectus Supplement dated March 1, 2021) Filed Pursuant to Rule 433 Registration Statement No.

Subject to completion, dated March 1, 2021

TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed.

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 26, 2021 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82

Offer letter for Eric Palmer dated December 6, 2020

Exhibit 10.35 David M. Cordani President and CEO Routing W2SLT 900 Cottage Grove Road Hartford, CT 06152 Telephone 860.226.7482 Facsimile 860.226.3099 December 6, 2020 Eric P. Palmer Dear Eric: I am pleased to offer the following compensation package in connection with your assumption of the role of President, Chief Operating Officer, Evernorth, reporting to Tim Wentworth, effective January 1, 202

Description of Securities

Exhibit 4.8 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a summary of the material terms of the Common Stock, par value $0.01 per share of Cigna Corporation (?Cigna? or the ?Company?). This summary is not complete and is qualified by Cigna?s amended and restated certificate of incorporation, which we refer to a

Subsidiaries of the Registrant

Exhibit 21 ? Subsidiaries of the Registrant Listed below are subsidiaries of Cigna Corporation as of December 31, 2020 with their jurisdictions of organization.

Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38769 Cigna Corporati

Cigna Corporation Director Equity Plan, as amended December 4, 2020

Exhibit 10.18 CIGNA CORPORATION DIRECTORS EQUITY PLAN (As Amended December 4, 2020) Article 1. Establishment and Purposes 1.1 Purpose. The Cigna Corporation Directors Equity Plan (the ?Plan?) is intended to (a) encourage ownership of the Company?s common stock by members of the Board of Directors of the Company (the ?Board?) who are not employees or officers of the Company and thereby align such d

Offer letter for Brian Evanko dated December 6, 2020

Exhibit 10.37 David M. Cordani President and CEO Routing W2SLT 900 Cottage Grove Road Hartford, CT 06152 Telephone 860.226.7482 Facsimile 860.226.3099 December 6, 2020 Brian Evanko Dear Brian: I am pleased to offer the following compensation package in connection with your assumption of the role of EVP & Chief Financial Officer, reporting to me, effective January 1, 2021, subject to your written a

Offer letter for Matthew Manders dated December 6, 2020

Exhibit 10.36 David M. Cordani President and CEO Routing W2SLT 900 Cottage Grove Road Hartford, CT 06152 Telephone 860.226.7482 Facsimile 860.226.3099 December 6, 2020 Matthew Manders Dear Matt: I am pleased to offer the following compensation package in connection with your assumption of the role of President, Government Business and Enterprise Solutions, reporting to me, effective January 1, 202

SCHEDULE 13G

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Cigna Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 125523100 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)*

SC 13G/A 1 tv0539-cignacorp.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Cigna Corp. Title of Class of Securities: Common Stock CUSIP Number: 125523100 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule purs

Cigna Reports Fourth Quarter and Full Year 2020 Results, Expects Continued Revenue and Earnings Growth in 2021

Exhibit 99.1 Press Release INVESTOR RELATIONS CONTACT: Alexis Jones 215-761-3637 [email protected] MEDIA CONTACT: Jim Cohn 224-214-8781 [email protected] Cigna Reports Fourth Quarter and Full Year 2020 Results, Expects Continued Revenue and Earnings Growth in 2021 • Total revenues for 2020 were $160.4 billion, and adjusted revenues1 for 2020 were $160.1 billion • Shareholders’ net income f

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 4, 2021 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-

Cigna Announces Appointment of George Kurian to Board of Directors

Exhibit 99.1 Cigna Announces Appointment of George Kurian to Board of Directors BLOOMFIELD, Conn., Jan 12, 2021 – Global health service company Cigna Corporation (NYSE:CI) today announced that George Kurian has been appointed to Cigna’s Board of Directors. His appointment is effective March 1, 2021. Mr. Kurian currently serves as chief executive officer of NetApp, Inc., a cloud-led, data-centric,

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - CIGNA CORPORATION FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 6, 2021 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-4

Regulation FD Disclosure - CIGNA CORPORATION FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 31, 2020 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 28, 2020 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - CIGNA CORPORATION FORM 8K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 8, 2020 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-

Cigna announces Leadership Changes to accelerate next phase of growth

Press Release Cigna announces Leadership Changes to accelerate next phase of growth ? Eric Palmer becomes president and chief operating officer of Evernorth ? Brian Evanko becomes chief financial officer of Cigna Corporation ? Matt Manders assumes leadership of government business as president, government and solutions of Cigna Corporation ? Everett Neville promoted to executive vice president, strategy and business development of Cigna Corporation ? Aparna Abburi promoted to president, Medicare ? Amy Bricker promoted to president, Express Scripts BLOOMFIELD, Conn.

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 10, 2020 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 30, 2020 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82